The Cannigma

MARCH 7, 2022

One trial has already made it to Phase II and is actively recruiting, meaning that it passed safety and tolerability studies in healthy patients, and trials in specific individuals are already underway. Preclinical studies by InMed Pharmaceuticals showed that CBN not only reduced markers of inflammation and pain, but also increased keratin.

THC 140

THC Sleep Clinical Trials Cannabinoids 140

MMJ Recs

JUNE 30, 2024

Ensuring the potency and safety of cannabis edibles and oils is paramount for patients reliant on their therapeutic benefits. These pharmaceutical-grade formulations provide patients with a discreet and easy-to-administer method of ingestion. Image by Nora Topicals on Unsplash.

Edibles 111

Edibles Oil Packaging Patients 111

The Cannigma

FEBRUARY 16, 2021

There is not extensive safety data available, however. Nanoemulsions can improve the bioavailability of pharmaceuticals and their uptake, and require less energy to break them down. They can also improve the penetration of topical solutions through skin lipids. What nanoemulsion means for cannabis products.

Edibles 138

Edibles Digestion Tincture Cannabinoids 138

Cannabis Law Report

DECEMBER 28, 2021

–(BUSINESS WIRE)– #pharma –Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX) achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below. “I About Virpax Pharmaceuticals. BERWYN, Pa.–(BUSINESS

Pharmaceutical 40

Pharmaceutical Research and Development Clinical Trials Chronic Pain 40

Cannabis Law Report

JUNE 21, 2021

Pharmaceutical companies use artificial intelligence (AI) to sort through reams of scientific data to find potentially effective active ingredients to be developed into approved drugs. A major oncology clinic aims to explore the efficacy and safety of cannabis to treat patients suffering from chronic pain. How to Use the Data.

Data 105

Data Clinical Trials Research and Development Indica 105

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders.

CBD 144

CBD Seed-To-Sale Food Access 144

TheAnswerPage

JUNE 12, 2022

A transdermal gel for regional and systemic delivery of CBD (Zynerba Pharmaceuticals) is in clinical development for treatment of epilepsy, developmental and epileptic encephalopathy, fragile-X syndrome, and osteoarthritis. A Review of the Safety and Effectiveness of Select Ingredients in Compounded Topical Pain Creams.”

Epilepsy 40

Epilepsy Topical Safety Treatment 40

TheAnswerPage

OCTOBER 11, 2021

A transdermal gel for regional and systemic delivery of CBD (Zynerba Pharmaceuticals) is in clinical development for treatment of epilepsy, developmental and epileptic encephalopathy, fragile-X syndrome, and osteoarthritis. A Review of the Safety and Effectiveness of Select Ingredients in Compounded Topical Pain Creams.”

Epilepsy 40

Epilepsy Topical Safety Treatment 40

Cannabis Law Report

JUNE 25, 2021

Major players in the global skin cancer drugs market are Novartis AG, Bristol Myers Squibb, Eli Lilly, Meda, and Sun Pharmaceutical Industries Ltd. The European Medicines Agency (EMA) is the regulatory body that evaluates and supervises the production and sales of medicines for safety and benefit of the customer, in the European Union Region.

Research and Development 65

Research and Development Therapy Pharmaceutical Clinical Trials 65

Cannabis Law Report

NOVEMBER 24, 2019

These events, amongst other drivers, have shown the obvious need to regulate product safety in CBD and THC products in a holistic and standardized way. a topical versus a suppository, can only be understood and captured by the producers themselves.

Business 95

Business Data Wellness and Beauty Safety 95

Canna Care Docs

OCTOBER 3, 2023

However, many of these pharmaceutical medications can just induce more unpleasant, debilitating effects on those who are ill. Depending on the type of terminal illness diagnosed by the doctor, there are numerous pharmaceutical and conventional medications provided for patients to treat the symptoms that come with a terminal illness.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

Cannabis Law Report

OCTOBER 22, 2021

Lenabasum: Corbus Pharmaceuticals Corbus Pharmaceuticals is developing Lenabasum, and currently it is in phase III stage of development for the treatment of multiple indications, such as dermatomyositis, systemic scleroderma, cystic fibrosis, systemic lupus erythematosus etc. Corbus Pharmaceuticals. TO Pharmaceuticals.

Research and Development 52

Research and Development Pharmaceutical Marijuana Chronic Pain 52

WeedAdvisor

JULY 21, 2019

In our past discussions on Colombia, one topic that came up was Colombia’s perfect setup for marijuana cultivation. South America needs safe, reliable growing materials, cannot use certain pesticides, needs to meet cleanliness and safety standards, etc. The checklist is endless, but every box needs to be marked.

Conditions 60

Conditions Seed-To-Sale Compliance Compliance 60

The Cannigma

JULY 1, 2022

There’s no doubt that the amount of information that is available about cannabis is at an all-time high – in 2020 alone, over 3,500 scientific articles were published on the topic. Moreover much of the research done has focused on synthetic pharmaceutical grade cannabinoids developed by pharmaceutical companies.

Research and Development 112

Research and Development Data THC Clinical Trials 112

Otherside Farms

JUNE 23, 2020

Pharmaceutical drugs may be prescribed by a doctor to help a person manage or treat depression. CBD has proven itself as a worthy alternative to pharmaceutical drugs. Many studies done on this topic have certain limitations. There are some concerns regarding the safety of such oils. What the Research Indicates.

CBD 52

CBD Wellness and Beauty Oil Pharmaceutical 52

Cannabis Law Report

MARCH 1, 2022

A fast-paced environment where you’ll work on a wide range of topics. Focus will be on IND/CTA filings and associated interactions, and may include safety reports, protocols, information amendments, responses to requests for information, IND Annual Reports/DSURs, and new investigator amendments. Position: Full-time. Opportunity.

Clinical Trials 52

Clinical Trials Environment Pharmaceutical Programs 52

Cannabis Law Report

OCTOBER 2, 2021

A fast-paced environment where you’ll work on a wide range of topics. Focus will be on IND/CTA filings and associated interactions, and may include safety reports, protocols, information amendments, responses to requests for information, IND Annual Reports/DSURs, and new investigator amendments. San Diego, United States. Opportunity.

Clinical Trials 52

Clinical Trials Environment Pharmaceutical Programs 52

SpeedWeed

MARCH 22, 2021

It went on to say: “The IASP has also published a list of research priorities which need to be addressed in order to properly determine the potential efficacy, and to confirm the safety of, cannabinoids when used in the treatment of pain.”. Not Closing The Door.

Business 52

Business Treatment Cannabinoids Medicine 52

Cannabis Law Report

NOVEMBER 22, 2019

She is currently a law school professor teaching Marijuana and the Law at California Western School of Law and researcher under a contract with NHTSA and NORC on the topic of the prosecution of drugged driving cases. Merrell Dow Pharmaceuticals, Inc., xxv] [link] ; [link] ; Barbuto v. Advantage Sales & Marketing, LLC , 477 Mass.

Research and Development 71

Research and Development Law Collective Concentrates 71

The Cannigma

JUNE 15, 2021

But the main issue with hemp derived products and their safety is less about the CBD and more about everything else in them. The main safety issues with CBD are drug interactions, and unsafe manufacturing processes due to the unregulated environment. . Dosing CBD products is different from the approach used with most pharmaceuticals.

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

MARCH 29, 2020

This “zero recall” standard, the team said, was attributed to the fact that their cannabis product standards with regard to food safety and health was high and involved documentation of over 100 pages. . These are the responsibility of the manufacturer. Setting Standards for Cannabis Research Studies .

Compliance 69

Compliance Compliance Supply Chain Research and Development 69

Cannabis Law Report

MARCH 30, 2020

Mr. Panter brings over 20 years of broad global supply chain experience at leading cosmetic, agriculture, pharmaceutical, medical device and consumer packaged goods (CPG) companies, including Estée Lauder Company, Luxottica Retail, Campbell Soup Company, and Tyco Healthcare/Covidien. ” Subscribe to Charlotte’s Web news.

Supply Chain 59

Supply Chain Extraction Hemp Pets 59

Cannabis Law Report

OCTOBER 18, 2021

Lenabasum: Corbus Pharmaceuticals. Corbus Pharmaceuticals is developing Lenabasum, and currently it is in phase III stage of development for the treatment of multiple indications, such as dermatomyositis, systemic scleroderma, cystic fibrosis, systemic lupus erythematosus etc. Cannabis oil: TO Pharmaceuticals. Key Players.

Research and Development 40

Research and Development Pharmaceutical Chronic Pain Therapy 40

Cannabis Law Report

DECEMBER 20, 2021

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. About Virpax Pharmaceuticals. Epoladerm™ is a topical diclofenac spray film formulation being developed to manage osteoarthritis pain. First Patient Expected to be Enrolled by Q2 of 2022. Data To Support Regulatory Filings in the United States.

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Data 40

The Cannigma

JUNE 16, 2022

Sure, it’s less addictive than some pharmaceutical drugs, with fewer side effects than most. A randomized, double-blinded, crossover trial tested the safety and efficacy of sublingual cannabis dosing in 23 people with insomnia. Strains mentioned in this article include: Harlequin Harmony Rose Ringo’s Gift ACDC. Easing insomnia.

Terpenes 104

Terpenes Strains Sleep THC 104

Cannabis Law Report

SEPTEMBER 20, 2021

The products leverage pharmaceutical technology to maximize performance and safety. Heritage believes in improving the lives of many who are dealing with chronic medical conditions with our well thought out, evidence based quality medical cannabis products that leverage innovative pharmaceutical technology.

Clinical Trials 40

Clinical Trials Pharmaceutical Data Patients 40

Cannabis Law Report

DECEMBER 8, 2021

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. The results of this study underscore the safety of our spray film technology.”. About Virpax Pharmaceuticals. Epoladerm™ is a topical diclofenac spray film formulation being developed to manage osteoarthritis pain. BERWYN, Pa.–(BUSINESS

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Topical 40

Cannabis Law Report

JUNE 10, 2021

that demonstrate the safety and anti-inflammatory, anti-aging, and antimicrobial properties of Willow CBG on human skin. The initial focus is on two product verticals: premium skincare and topical athletic recovery products to be launched from this autumn. based provider of premium consumer products based on biosynthetic cannabinoids.

Research and Development 66

Research and Development Cannabinoids Pharmaceutical Policy 66

Cannabis Law Report

SEPTEMBER 28, 2021

Epidiolex (formerly, GWP42003-P) is an oral cannabidiol solution that GW Pharmaceuticals developed. Ganaxolone: Marinus Pharmaceuticals. XEN496: Xenon Pharmaceuticals. Key Topics Covered: Introduction. OPC-214870: Otsuka Pharmaceutical. Epilepsy Emerging Drugs. GWP42003-P: GW Research. Major Players in Epilepsy.

Epilepsy 40

Epilepsy Clinical Trials Research and Development Pharmaceutical 40

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. SOURCE InMed Pharmaceuticals Inc.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. SOURCE InMed Pharmaceuticals Inc.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Cannabis Law Report

JULY 1, 2021

In the following interview, which has been edited and condensed, Senior Fellow and POPLAR Project Lead Mason Marks explains how POPLAR will fill this gap, and previews some of the initiative’s topics of inquiry. Mason Marks: The project’s goal is to promote safety, innovation, equity, and accessibility in emerging psychedelics industries.

Law 81

Law Research and Development Therapy DEA 81

The Herb Collective

APRIL 2, 2021

You can use more common methods like topical treatments, CBD edibles, and even CBD joints; but among the endless options, there is one intriguing form of CBD use– vaping! To make sure you can trust the safety of your CBD vape, start by making sure you are buying a legal and lab-tested product from a trusted retailer.

Vaping 52

Vaping CBD Sleep Oil 52

Cannabis Law Report

JANUARY 11, 2019

Food and Drug Administration (FDA) retains its authority to regulate ingestible and topical products, including those that contain hemp and hemp extracts such as CBD. Food and supplements that contain hemp-derived CBD are subject to a comprehensive regulatory framework that addresses both the safety and quality of these products.

Hemp 49

Hemp CBD Law Seed-To-Sale 49

Connor & Connor PLLC

APRIL 12, 2019

However, most of these moms are also looking to avoid taking pharmaceuticals for these issues. After extensive research since 2017, CBD has a favorable safety profile. Additionally, topical usage of CBD was noted as valuable when inflammation and joint pain is present. In the End.

Oil 68

Oil CBD Research and Development THC 68

Cannabis Law Report

DECEMBER 22, 2019

The information came alongside the firm’s release of a for-purchase report on the topic. For instance, in April 2018, Gala Pharmaceutical, Inc. Related Market Reports on similar Topics: Global Cannabis Testing Services Market. per cent over the 2019 – 2027 period. Request your Sample PDF copy @ [link]. Research Institutes.

Blood Pressure 45

Blood Pressure Concentrates Medicine Terpenes 45

Puff Puff Post

DECEMBER 2, 2019

Many of the safety issues in the report involve the use of CBD without the guidance of a health care professional. One of the reasons for its growth potential is its pharmaceutical application in products such as Epidiolex. Walgreens issued a similar statement on their website announcing their intention to carry certain topicals.

CBD 52

CBD Food Pets Safety 52